Dr. Gerard Criner Leads Analyses That Could Identify Group of Patients with COPD Likely to Benefit from Asthma Drug Benralizumab

Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, was the corresponding author on new hypothesis-generating analyses of the Phase III international clinical trials GALATHEA and TERRANOVA published in The Lancet Respiratory Medicine and presented at the European Respiratory Society International Congress. The new analyses identified clinical and physiological characteristics of patients with COPD that could help identify those who are likely to have the greatest treatment effect with benralizumab. MedPage Today, Bioengineer.org, News-Medical.net and other media outlets reported on the findings.